Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity

Changyou Zhou, Margareta Garcia-Calvo, Shirly Pinto, Matthew Lombardo, Zhe Feng, Kate Bender, Kellyann D. Pryor, Urmi R. Bhatt, Renee M. Chabin, Wayne M. Geissler, Zhu Shen, Xinchun Tong, Zhoupeng Zhang, Kenny K. Wong, Ranabir Sinha Roy, Kevin T. Chapman, Lihu Yang, Yusheng Xiong

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Abstract

Prolylcarboxypeptidase (PrCP) is a serine protease that may have a role in metabolism regulation. A class of reversible, potent, and selective PrCP inhibitors was developed starting from a mechanism based design for inhibiting this serine protease. Compound 8o inhibits human and mouse PrCP at IC 50 values of 1 and 2 nM and is not active (IC50 > 25 μM) against a panel of closely related proteases. It has lower serum binding than its close analogues and is bioavailable in mouse. Subchronic dosing of 8o in PrCP-/- and WT mice at 100 mg/kg for 5 days resulted in a 5% reduction in body weight in WT mice and a 1% reduction in PrCP KO mice.

Original languageEnglish
Pages (from-to)7251-7263
Number of pages13
JournalJournal of Medicinal Chemistry
Volume53
Issue number19
DOIs
StatePublished - 14 Oct 2010

Fingerprint

Dive into the research topics of 'Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity'. Together they form a unique fingerprint.

Cite this